Paper of the Month: Biomarkers for Neoadjuvant PD-L1 Therapy

By The Uromigos - Last Updated: June 16, 2023

Joshua Meeks, MD, PhD, joins the podcast to discuss his paper published in Nature Communications on the use of expression-based subtypes to define pathologic response to neoadjuvant immune-checkpoint inhibitors in patients with muscle-invasive bladder cancer.
Dr. Meeks is an associate professor of Urology and Biochemistry and Molecular Genetics at the Northwestern Medicine Feinberg School of Medicine.

Post Tags:Uromigos-Bladder Cancer